Adoptive immunotherapy of cancer using ex vivo expanded human γδ T cells: A new approach

Cancer Letters

Volumn 297, Issue 1, 2010, Pages 126-136

  Dokouhaki, Pouneh ^a   Han, Mei ^a   Joe, Betty ^a   Li, Ming ^b   Johnston, Michael R ^a   Tsao, Ming Sound ^b   Zhang, Li ^a,b,c  

^a UNIVERSITY HEALTH NETWORK   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

T cells; Adoptive T cell immunotherapy; Cancer immunotherapy

Indexed keywords

ADOPTIVE IMMUNOTHERAPY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BODY WEIGHT; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOTOXICITY; EX VIVO STUDY; FLOW CYTOMETRY; GAMMA DELTA T LYMPHOCYTE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INNATE IMMUNITY; LYMPHOCYTE FUNCTION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PURIFICATION; T LYMPHOCYTE; TUMOR VOLUME; TUMOR XENOGRAFT; ANIMAL; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL SEPARATION; DRUG SCREENING; IMMUNOLOGY; JURKAT CELL LINE; LUNG NEOPLASMS; METABOLISM; PATHOLOGY; PROCEDURES; SCID MOUSE; U937 CELL LINE;

ANIMALS; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL SEPARATION; CYTOTOXICITY, IMMUNOLOGIC; HUMANS; IMMUNOTHERAPY, ADOPTIVE; INTERFERON-GAMMA; JURKAT CELLS; LUNG NEOPLASMS; MICE; MICE, SCID; RECEPTORS, ANTIGEN, T-CELL, GAMMA-DELTA; T-LYMPHOCYTES; TUMOR BURDEN; U937 CELLS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

GAMMA INTERFERON; LYMPHOCYTE ANTIGEN RECEPTOR;

EID: 77956225253     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2010.05.005     Document Type: Article

References (53)

1. Hayday A.C. [Gamma][delta] cells: a right time and a right place for a conserved third way of protection. Annu. Rev. Immunol. 2000, 18:975-1026.
2. Thedrez A., Sabourin C., Gertner J., Devilder M.C., lain-Maillet S., Fournie J.J., Scotet E., Bonneville M. Self/non-self discrimination by human gammadelta T cells: simple solutions for a complex issue?. Immunol. Rev. 2007, 215:123-135.
3. Xu C., Zhang H., Hu H., He H., Wang Z., Xu Y., Chen H., Cao W., Zhang S., Cui L., Ba D., He W. Gammadelta T cells recognize tumor cells via CDR3delta region. Mol. Immunol. 2007, 44:302-310.
4. Corvaisier M., Moreau-Aubry A., Diez E., Bennouna J., Mosnier J.F., Scotet E., Bonneville M., Jotereau F. V gamma 9V delta 2 T cell response to colon carcinoma cells. J. Immunol. 2005, 175:5481-5488.
5. Choudhary A., Davodeau F., Moreau A., Peyrat M.A., Bonneville M., Jotereau F. Selective lysis of autologous tumor cells by recurrent gamma delta tumor-infiltrating lymphocytes from renal carcinoma. J. Immunol. 1995, 154:3932-3940.
6. Kabelitz D. Effector functions and control of human gammadelta T-cell activation. Microbes Infect. 1999, 1:255-261.
7. Kabelitz D., Wesch D., He W. Perspectives of gammadelta T cells in tumor immunology. Cancer Res. 2007, 67:5-8.
8. Brandes M., Willimann K., Moser B. Professional antigen-presentation function by human gammadelta T Cells. Science 2005, 309:264-268.
9. Brandes M., Willimann K., Bioley G., Levy N., Eberl M., Luo M., Tampe R., Levy F., Romero P., Moser B. Cross-presenting human gammadelta T cells induce robust CD8+ alphabeta T cell responses. Proc. Natl. Acad. Sci. USA 2009, 106:2307-2312.
10. Rosenberg S.A., Restifo N.P., Yang J.C., Morgan R.A., Dudley M.E. Adoptive cell transfer: a clinical path to effective cancer immunotherapy. Nat. Rev. Cancer 2008, 8:299-308.
11. Hunder N.N., Wallen H., Cao J., Hendricks D.W., Reilly J.Z., Rodmyre R., Jungbluth A., Gnjatic S., Thompson J.A., Yee C. Treatment of metastatic melanoma with autologous CD4+ T cells against NY-ESO-1. New Engl. J. Med. 2008, 358:2698-2703.
12. Srivastava S., Lundqvist A., Childs R.W. Natural killer cell immunotherapy for cancer: a new hope. Cytotherapy 2008, 10:775-783.
13. Kabelitz D., Wesch D. Features and functions of gamma delta T lymphocytes: focus on chemokines and their receptors. Crit. Rev. Immunol. 2003, 23:339-370.
14. Tanaka Y., Morita C.T., Tanaka Y., Nieves E., Brenner M.B., Bloom B.R. Natural and synthetic non-peptide antigens recognized by human [gamma][delta] T cells. Nature 1995, 375:155-158.
15. Espinosa E., Belmant C., Pont F., Luciani B., Poupot R., Romagne F., Brailly H., Bonneville M., Fournie J.J. Chemical Synthesis and biological activity of bromohydrin pyrophosphate, a potent stimulator of human gamma delta T cells. J. Biol. Chem. 2001, 276:18337-18344.
16. Bennouna J., Bompas E., Neidhardt E.M., Rolland F., Philip I., Galea C., Salot S., Saiagh S., Audrain M., Rimbert M., Lafaye-de M.S., Tiollier J., Negrier S. Phase-I study of Innacell gammadelta, an autologous cell-therapy product highly enriched in gamma9delta2 T lymphocytes, in combination with IL-2, in patients with metastatic renal cell carcinoma. Cancer Immunol. Immunother. 2008, 57:1599-1609.
17. Viey E., Laplace C., Escudier B. Peripheral gammadelta T-lymphocytes as an innovative tool in immunotherapy for metastatic renal cell carcinoma. Expert Rev. Anticancer Ther. 2005, 5:973-986.
18. Maeurer M.J., Martin D., Walter W., Liu K., Zitvogel L., Halusczcak K., Rabinowich H., Duquesnoy R., Storkus W., Lotze M.T. Human intestinal Vdelta1+ lymphocytes recognize tumor cells of epithelial origin. J. Exp. Med. 1996, 183:1681-1696.
19. Poggi A., Venturino C., Catellani S., Clavio M., Miglino M., Gobbi M., Steinle A., Ghia P., Stella S., Caligaris-Cappio F., Zocchi M.R. Vdelta1 T lymphocytes from B-CLL patients recognize ULBP3 expressed on leukemic B cells and up-regulated by trans-retinoic acid. Cancer Res. 2004, 64:9172-9179.
20. Meeh P.F., King M., O'Brien R.L., Muga S., Buckhalts P., Neuberg R., Lamb L.S. Characterization of the gammadelta T cell response to acute leukemia. Cancer Immunol. Immunother. 2006, 55:1072-1080.
21. Lopez R.D., Xu S., Guo B., Negrin R.S., Waller E.K. CD2-mediated IL-12-dependent signals render human gamma delta-T cells resistant to mitogen-induced apoptosis, permitting the large-scale ex vivo expansion of functionally distinct lymphocytes: implications for the development of adoptive immunotherapy strategies. Blood 2000, 96:3827-3837.
22. Bryant N.L., Suarez-Cuervo C., Gillespie G.Y., Markert J.M., Nabors L.B., Meleth S., Lopez R.D., Lamb L.S. Characterization and immunotherapeutic potential of gammadelta T-cells in patients with glioblastoma. Neuro Oncol. 2009, 11:357-367.
23. Guo B.L., Liu Z., Aldrich W.A., Lopez R.D. Innate anti-breast cancer immunity of apoptosis-resistant human gammadelta-T cells. Breast Cancer Res. Treat. 2005, 93:169-175.
24. Liu Z., Guo B.L., Gehrs B.C., Nan L., Lopez R.D. Ex vivo expanded human Vgamma9Vdelta2+ gammadelta-T cells mediate innate antitumor activity against human prostate cancer cells in vitro. J. Urol. 2005, 173:1552-1556.
25. Liu J., Blackhall F., Seiden-Long I., Jurisica I., Navab R., Liu N., Radulovich N., Wigle D., Sultan M., Hu J., Tsao M.S., Johnston M.R. Modeling of lung cancer by an orthotopically growing H460SM variant cell line reveals novel candidate genes for systemic metastasis. Oncogene 2004, 23:6316-6324.
26. Topalian S.L., Solomon D., Rosenberg S.A. Tumor-specific cytolysis by lymphocytes infiltrating human melanomas. J. Immunol. 1989, 142:3714-3725.
27. Zhang Z.X., Yang L., Young K.J., DuTemple B., Zhang L. Identification of a previously unknown antigen-specific regulatory T cell and its mechanism of suppression. Nat. Med. 2000, 6:782-789.
28. Euhus D.M., Hudd C., LaRegina M.C., Johnson F.E. Tumor measurement in the nude mouse. J. Surg. Oncol. 1986, 31:229-234.
29. Klebanoff C.A., Gattinoni L., Restifo N.P. CD8+ T-cell memory in tumor immunology and immunotherapy. Immunol. Rev. 2006, 211:214-224.
30. Caccamo N., Meraviglia S., Ferlazzo V., Angelini D., Borsellino G., Poccia F., Battistini L., Dieli F., Salerno A. Differential requirements for antigen or homeostatic cytokines for proliferation and differentiation of human Vgamma9Vdelta2 naive, memory and effector T cell subsets. Eur. J. Immunol. 2005, 35:1764-1772.
31. Yamaguchi T., Fujimiya Y., Suzuki Y., Katakura R., Ebina T. A simple method for the propagation and purification of [gamma][delta]T cells from the peripheral blood of glioblastoma patients using solid-phase anti-CD3 antibody and soluble IL-2. J. Immunol. Methods 1997, 205:19-28.
32. Wilhelm M., Kunzmann V., Eckstein S., Reimer P., Weissinger F., Ruediger T., Tony H.P. Gammadelta T cells for immune therapy of patients with lymphoid malignancies. Blood 2003, 102:200-206.
33. Kabelitz D., Wesch D., Pitters E., Zoller M. Potential of human gammadelta T lymphocytes for immunotherapy of cancer. Int. J. Cancer 2004, 112:727-732.
34. Ferrarini M., Heltai S., Pupa S.M., Mernard S., Zocchi R. Killing of laminin receptor-positive human lung cancers by tumor infiltrating lymphocytes bearing gammadelta(+) t-cell receptors. J. Natl. Cancer Inst. 1996, 88:436-441.
35. Groh V., Rhinehart R., Secrist H., Bauer S., Grabstein K.H., Spies T. Broad tumor-associated expression and recognition by tumor-derived gamma delta T cells of MICA and MICB. Proc. Natl. Acad. Sci. USA 1999, 96:6879-6884.
36. Ebert L.M., Meuter S., Moser B. Homing and function of human skin gammadelta T cells and NK cells: relevance for tumor surveillance. J. Immunol. 2006, 176:4331-4336.
37. Tran K.Q., Zhou J., Durflinger K.H., Langhan M.M., Shelton T.E., Wunderlich J.R., Robbins P.F., Rosenberg S.A., Dudley M.E. Minimally cultured tumor-infiltrating lymphocytes display optimal characteristics for adoptive cell therapy. J. Immunother. 2008, 31:742-751.
38. Ferrarini M., Delfanti F., Gianolini M., Rizzi C., Alfano M., Lazzarin A., Biswas P. NF-kappa B modulates sensitivity to apoptosis, proinflammatory and migratory potential in short - versus long - term cultured human gamma delta lymphocytes. J. Immunol. 2008, 181:5857-5864.
39. Robbins P.F., Dudley M.E., Wunderlich J., El-Gamil M., Li Y.F., Zhou J., Huang J., Powell D.J., Rosenberg S.A. Cutting edge: persistence of transferred lymphocyte clonotypes correlates with cancer regression in patients receiving cell transfer therapy. J. Immunol. 2004, 173:7125-7130.
40. Gattinoni L., Klebanoff C.A., Palmer D.C., Wrzesinski C., Kerstann K., Yu Z., Finkelstein S.E., Theoret M.R., Rosenberg S.A., Restifo N.P. Acquisition of full effector function in vitro paradoxically impairs the in vivo antitumor efficacy of adoptively transferred CD8+ T cells. J. Clin. Invest. 2005, 115:1616-1626.
41. Dieli F., Poccia F., Lipp M., Sireci G., Caccamo N., Di S.C., Salerno A. Differentiation of effector/memory Vdelta2 T cells and migratory routes in lymph nodes or inflammatory sites. J. Exp. Med. 2003, 198:391-397.
42. Dieli F., Gebbia N., Poccia F., Caccamo N., Montesano C., Fulfaro F., Arcara C., Valerio M.R., Meraviglia S., Di S.C., Sireci G., Salerno A. Induction of gammadelta T-lymphocyte effector functions by bisphosphonate zoledronic acid in cancer patients in vivo. Blood 2003, 102:2310-2311.
43. Salot S., Laplace C., Saiagh S., Bercegeay S., Tenaud I., Cassidanius A., Romagne F., Dreno B., Tiollier J. Large scale expansion of gamma 9 delta 2 T lymphocytes: Innacell gamma delta cell therapy product. J. Immunol. Methods 2007, 326:63-75.
44. Chen L., He W., Kim S.T., Tao J., Gao Y., Chi H., Intlekofer A.M., Harvey B., Reiner S.L., Yin Z., Flavell R.A., Craft J. Epigenetic and transcriptional programs lead to default IFN-gamma production by gammadelta T cells. J. Immunol. 2007, 178:2730-2736.
45. Alexander A.A., Maniar A., Cummings J.S., Hebbeler A.M., Schulze D.H., Gastman B.R., Pauza C.D., Strome S.E., Chapoval A.I. Isopentenyl pyrophosphate-activated CD56+ {gamma}{delta} T lymphocytes display potent antitumor activity toward human squamous cell carcinoma. Clin. Cancer Res. 2008, 14:4232-4240.
46. Kabelitz D., Wesch D., Pitters E., Zoller M. Characterization of tumor reactivity of human V gamma 9V delta 2 gamma delta T cells in vitro and in SCID mice in vivo. J. Immunol. 2004, 173:6767-6776.
47. Zheng B.J., Chan K.W., Im S., Chua D., Sham J.S., Tin P.C., He Z.M., Ng M.H. Anti-tumor effects of human peripheral gammadelta T cells in a mouse tumor model. Int. J. Cancer 2001, 92:421-425.
48. Yuasa T., Sato K., Ashihara E., Takeuchi M., Maita S., Tsuchiya N., Habuchi T., Maekawa T., Kimura S. Intravesical administration of gammadelta T cells successfully prevents the growth of bladder cancer in the murine model. Cancer Immunol. Immunother. 2009, 58:493-502.
49. Mincheva-Nilsson L., Nagaeva O., Sundqvist K.G., Hammarstrom M.L., Hammarstrom S., Baranov V. Gammadelta T cells of human early pregnancy decidua: evidence for cytotoxic potency. Int. Immunol. 2000, 12:585-596.
50. Narazaki H., Watari E., Shimizu M., Owaki A., Das H., Fukunaga Y., Takahashi H., Sugita M. Perforin-dependent killing of tumor cells by Vgamma1Vdelta1-bearing T-cells. Immunol. Lett. 2003, 86:113-119.
51. Mirandola P., Ponti C., Gobbi G., Sponzilli I., Vaccarezza M., Cocco L., Zauli G., Secchiero P., Manzoli F.A., Vitale M. Activated human NK and CD8+ T cells express both TNF-related apoptosis-inducing ligand (TRAIL) and TRAIL receptors but are resistant to TRAIL-mediated cytotoxicity. Blood 2004, 104:2418-2424.
52. Zamai L., Ahmad M., Bennett I.M., Azzoni L., Alnemri E.S., Perussia B. Natural killer (NK) cell-mediated cytotoxicity: differential use of TRAIL and Fas ligand by immature and mature primary human NK cells. J. Exp. Med. 1998, 188:2375-2380.
53. Bouet-Toussaint F., Cabillic F., Toutirais O., Le G.M., Thomas de la P.C., Daniel P., Genetet N., Meunier B., Dupont-Bierre E., Boudjema K., Catros V. Vgamma9Vdelta2 T cell-mediated recognition of human solid tumors. Potential for immunotherapy of hepatocellular and colorectal carcinomas. Cancer Immunol. Immunother. 2008, 57:531-539.